8-K: Anteris Technologies Announces $250M ATM Offering

Anteris Technologies Global Corp. has entered into a sales agreement with TD Securities (USA) LLC to offer and sell up to $250 million of its common stock through an at-the-market (ATM) program.

Summary

• The company entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) on May 22, 2026.
• The agreement allows for the sale of common stock with an aggregate offering price of up to $250,000,000.
• Sales will be conducted as 'at-the-market' offerings, including through the Nasdaq Global Market or negotiated transactions.
• TD Cowen will receive a 3.0% commission on the gross proceeds of any shares sold.
• The company intends to use the net proceeds primarily for the development of its DurAVR Transcatheter Heart Valve System, with the remainder for working capital and general corporate purposes.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine financial maneuver; while it provides necessary capital for R&D, it signals potential future dilution for shareholders.

Positives

• Provides the company with flexible access to capital to fund the ongoing development of the DurAVR Transcatheter Heart Valve System.
• The ATM structure allows the company to raise capital opportunistically based on market conditions.
• The agreement includes standard indemnification and contribution provisions for both parties.

Negatives

• The issuance of additional shares will result in dilution to existing shareholders.
• The company incurs costs associated with the offering, including a 3.0% sales commission and legal/filing expenses.
• The company cannot provide assurance that any shares will be sold under the agreement.

Risks

• Potential for significant dilution of existing shareholders if the full $250 million is raised.
• Market volatility could impact the ability to sell shares at favorable prices.
• The agreement may be terminated by either party, potentially disrupting planned capital raises.
• The company's reliance on the success of the DurAVR system development remains a primary business risk.

Future Outlook

The company intends to utilize the net proceeds from the offering to advance the development of its DurAVR Transcatheter Heart Valve System and for general corporate purposes.

Management Comments

• The company has not provided specific forward-looking commentary beyond the stated intent to use proceeds for the DurAVR system development.

Industry Context

StockSavvy.ai notes that at-the-market (ATM) offerings are a common capital-raising tool for clinical-stage medical device and biotech companies to extend their cash runway without the immediate market impact of a traditional underwritten follow-on offering.

Comparison to Industry Standards

• The 3.0% commission rate is consistent with standard market practices for ATM programs.
• The use of an S-3 shelf registration for an ATM program is a standard mechanism for Nasdaq-listed companies to maintain financial flexibility.

Stakeholder Impact

• Shareholders: Potential for dilution of ownership interest.
• Company: Increased liquidity to fund R&D and operations.

Next Steps

• The company may issue Placement Notices to TD Cowen to initiate sales of common stock.
• The company will disclose the number of shares sold and net proceeds in its subsequent quarterly (10-Q) and annual (10-K) reports.

Key Dates

Recommendation

The establishment of an ATM program is a standard capital-raising activity. Investors should hold until the company provides updates on the actual utilization of the facility and the progress of the DurAVR clinical development.

Keywords

Anteris Technologies, ATM Offering, DurAVR, Capital Raise, Biotech, Medical Devices, AVR